Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review Article About Some Herbs Affecting Vitiligo Based on Avicenna’s Canon

Author(s): Marjan Mahjour* and Arash Khoushabi

Volume 17, Issue 2, 2020

Page: [133 - 137] Pages: 5

DOI: 10.2174/1570163815666181017100847

Price: $65

Abstract

Background: Vitiligo is a pigmentary disorder characterizing by white macules due to loss of melanocytes. Vitiligo affects about 1 to 4% of people around the world. The treatment of vitiligo has a high cost and the long process of treatment in spite of no complete remedy. It has various psychological side-effects such as depression and anxiety affecting the quality of life seriously. Avicenna in his Canon treated these patients over a thousand years ago. This study aimed to introduce some herbal drugs in vitiligo based on the Canon of Avicenna besides the conventional medical treatments.

Methods: This is a review study, according to the Canon with the term Baras and also searching through the electronic websites with the keywords vitiligo, treatment, and herbal drugs.

Results: The study found some herbs affecting the vitiligo from the Canon.

Conclusion: The researchers suggest conducting clinical trials on the patients with vitiligo based on the Canon besides the conventional techniques to obtain a better result in the treatment.

Keywords: Vitiligo, Baras, persian medicine, avicenna, herbs, pigmentary disorder.

Graphical Abstract

[1]
Manga P, Elbuluk N, Orlow SJ. Recent advances in understanding vitiligo. F1000Research 2016 09/06 09/02/accepted; 5: F1000 Faculty Rev-2234
[2]
Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: A meta-analysis. PLoS One 2016; 11(9)e0163806
[http://dx.doi.org/10.1371/journal.pone.0163806] [PMID: 27673680]
[3]
Boniface K, Seneschal J, Picardo M, Taïeb A. Vitiligo: Focus on clinical aspects, immunopathogenesis, and therapy. Clin Rev Allergy Immunol 2018; 54(1): 52-67.
[http://dx.doi.org/10.1007/s12016-017-8622-7] [PMID: 28685247]
[4]
Szczurko O, Boon HS. A systematic review of natural health product treatment for vitiligo. BMC Dermatol 2008; 8(1): 2.
[http://dx.doi.org/10.1186/1471-5945-8-2] [PMID: 18498646]
[5]
Donga M-H, Lib S-M, Lin R-B, Eds. Effect of psychological intervention on treatment and quality of life of patients with vitiligo. Proceedings of the 2015 International Conference.
[http://dx.doi.org/10.1142/9789814719810_0014]
[6]
Ongenae K, Beelaert L, van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol 2006; 20(1): 1-8.
[http://dx.doi.org/10.1111/j.1468-3083.2005.01369.x] [PMID: 16405601]
[7]
Porter JR, Beuf AH, Lerner AB, Nordlund JJ. The effect of vitiligo on sexual relationships. J Am Acad Dermatol 1990; 22(2 Pt 1): 221-2.
[http://dx.doi.org/10.1016/0190-9622(90)70028-G] [PMID: 2312803]
[8]
Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2(3): 167-81.
[http://dx.doi.org/10.2165/00128071-200102030-00006] [PMID: 11705094]
[9]
Marjan M, Arash K. Effectiveness of Cicer Arietinum in Cutaneous Problems: View-point of Avicenna and Razi. Curr Drug Discov Technologies 2018; 15(3): 1-8.
[10]
Ibn Sina H’. Canon of Medicine J R Soc Med 2009 102(2) 2005
[11]
Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. Elsevier Saunders 2016.
[12]
Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients’ sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90(6): 783-9.
[http://dx.doi.org/10.1111/1523-1747.ep12461505] [PMID: 3373009]
[13]
Solak B, Dikicier BS, Cosansu NC, Erdem T. Effects of age of onset on disease characteristics in non-segmental vitiligo. Int J Dermatol 2017; 56(3): 341-5.
[http://dx.doi.org/10.1111/ijd.13425] [PMID: 28054375]
[14]
Iannella G, Greco A, Didona D, et al. Vitiligo: Pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2016; 15(4): 335-43.
[http://dx.doi.org/10.1016/j.autrev.2015.12.006] [PMID: 26724277]
[15]
Li S, Zhu G, Yang Y, et al. Oxidative stress drives CD8+ T-cell skin trafficking in pa-tients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes. Journal of Al-lergy and Clinical Immunology 2017; 140(1): 177-89. e9.
[16]
Grimes PE, Nashawati R. The Role of Diet and Supplements in Vitiligo Management. Dermatol Clin 2017; 35(2): 235-43.
[http://dx.doi.org/10.1016/j.det.2016.11.012] [PMID: 28317532]
[17]
Frisoli ML, Harris JE. Vitiligo: Mechanistic insights lead to novel treatments. J Allergy Clin Immunol 2017; 140(3): 654-62.
[http://dx.doi.org/10.1016/j.jaci.2017.07.011] [PMID: 28778794]
[18]
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 2017; 77(1): 1-13.
[http://dx.doi.org/10.1016/j.jaad.2016.10.048] [PMID: 28619550]
[19]
Rashighi M, Harris JE. Vitiligo pathogenesis and emerging treatments. Dermatol Clin 2017; 35(2): 257-65.
[http://dx.doi.org/10.1016/j.det.2016.11.014] [PMID: 28317534]
[20]
Mohammad TF, Hamzavi IH. Surgical Therapies for Vitiligo. Dermatol Clin 2017; 35(2): 193-203.
[http://dx.doi.org/10.1016/j.det.2016.11.009] [PMID: 28317528]
[21]
Cunha PR, Scabine Pessotti N, Bonati Mattos C, Salai AF. New approach in the treatment of refractory vitiligo: CO2 laser combined with betamethasone and salicylic acid solution. Dermatol Ther (Heidelb) 2017; 30(1)e12410
[http://dx.doi.org/10.1111/dth.12410] [PMID: 27548998]
[22]
Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32- week open-label extension study with op-tional narrow-band ultraviolet B. Journal of the American Academy of Dermatology 2018; 78(6): 1205-07. e1.
[23]
Ghorbanibirgani A, Khalili A, Rokhafrooz D. Comparing Nigella sativa Oil and Fish Oil in Treatment of Vitiligo. Iran Red Crescent Med J 2014; 16(6)e4515
[http://dx.doi.org/10.5812/ircmj.4515] [PMID: 25068060]
[24]
Khemis A, Ortonne JP. Comparative study of vegetable extracts possessing active superoxide dismutase and catalase (Vitix) plus selective UVB phototherapy versus an excipient plus selective UVB phototherapy in the treatment of common vitiligo. Nouvelles Dermatologiques 2004; 23(1): 45-6.
[25]
Djerrou Z. Successful treatment of facial vitiligo with honey bee, Allium cepa and Avena sativa combined to sun light exposure: A case clinical trial. Int J of Pharmaceut Clin Res 2015; 7(1): 9-14.
[26]
Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol 2003; 28(3): 285-7.
[http://dx.doi.org/10.1046/j.1365-2230.2003.01207.x] [PMID: 12780716]
[27]
Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 2011; 11(1): 21.
[http://dx.doi.org/10.1186/1472-6882-11-21] [PMID: 21406109]
[28]
Babitha S, Nguyen DH, Park S-J, et al. Potential of Cassia alata leaf extract in inducing differentiation and migration of mouse melanoblasts. Biotechnol Bioprocess Eng; BBE 2010; 15(6): 1071-6.
[http://dx.doi.org/10.1007/s12257-010-0121-0]
[29]
Mahendra AA, Bandara GK, Rohinie GA, Disala JC. Studies on the composition and standardization of “Bakuchi Oil”, an ayurvedic medicinal oil prepared from psoralea corylifolia L. used in the treatment of Vitiligo. Int J Res Ayurveda Pharm 2012; 3: 411-5.
[30]
Magilavy D. Treatment for vitiligo. Us Patent 9730930 August 15, 2017.
[31]
Korobko IV. Review of current clinical studies of vitiligo treatments. Dermatol Ther (Heidelb) 2012; 25(Suppl. 1): S17-27.
[http://dx.doi.org/10.1111/dth.12008] [PMID: 23237034]
[32]
Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013; 168(1): 5-19.
[http://dx.doi.org/10.1111/j.1365-2133.2012.11197.x] [PMID: 22860621]
[33]
Jain R, Narang T, Chetlapalli SS. Inventors Method for treating vitiligo with a prostaglandin an-alogue. Us Patent App 13194458 October 04 2012.
[34]
Topical preparation containing ngf for inducing skin pigmen-tation and for the treatment of cutaneous dyschromias and vitiligo. US Patent 9402906 August 02, 2016.
[35]
Fleming T. PDR for herbal medicines. Montvale, NJ: Medical Economics Company. vi 2000.
[36]
Duke JA. CRC handbook of medicinal spices. CRC press 2002.
[http://dx.doi.org/10.1201/9781420040487]
[37]
Gülçin I, Topal F, Sarikaya SBÖ, et al. Polyphenol Contents and Antioxidant Properties of Medlar (Mespilus germanica L. Rec Nat Prod 2011; 5(3): 158.

Rights & Permissions Print Cite
Article Metrics
52
7
© 2024 Bentham Science Publishers | Privacy Policy